

Review: Short vs. long duration dual antiplatelet Tx after stent

June 5 2015



(HealthDay)—Dual antiplatelet therapy (DAPT) continued beyond six months after drug-eluting stent implantation is associated with reduced stent thrombosis and myocardial infarction but also increased bleeding and all-cause mortality as compared to shorter-term DAPT therapy, according to a review published online May 25 in *Cardiovascular Therapeutics*.

Elsayed Abo-salem, M.D., from the University of Cincinnati, and colleagues conducted a systematic literature review to compare continued use of DAPT with shorter duration DAPT (aspirin alone) for variable durations beyond three months of drug-eluting stent implantation. Data were included from 10 [randomized controlled trials](#) involving 32,136 subjects randomized to continued use of DAPT versus aspirin alone.

The researchers found that longer DAPT correlated with a significant reduction in [stent thrombosis](#) (0.3 versus 0.7 percent; P

"DAPT continued beyond six months after second generation drug-eluting stent implantation decreases stent thrombosis and [myocardial infarction](#), but increases [major bleeding](#) and all-causes mortality compared to shorter DAPT (aspirin alone)," the authors conclude.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Review: Short vs. long duration dual antiplatelet Tx after stent (2015, June 5) retrieved 11 May 2024 from <https://medicalxpress.com/news/2015-06-short-duration-dual-antiplatelet-tx.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.